Searchable abstracts of presentations at key conferences in endocrinology

ea0081p288 | Calcium and Bone | ECE2022

Tumour induced osteomalacia: 2 years treatment with burosumab

Aliberti Ludovica , Pontrelli Margherita , Verrienti Martina , Gagliardi Irene , Zatelli Maria Chiara , Ambrosio Maria Rosaria

Introduction: Tumor-induced osteomalacia (TIO) is a paraneoplastic syndrome due to an overproduction of fibroblast growth factor 23 (FGF23) by small and benign mesenchimal tumors. FGF23 increase causes hypophosphatemia, osteomalacia and muscle weakness. TIO is usually cured by tumour resection, but neoplasms may be unidentifiable/unresectable or the patient may refuse surgery. In these cases, medical treatment with high doses of oral phosphate and calcitriol is mandatory, even...

ea0081p555 | Calcium and Bone | ECE2022

Thalassemia major: prevalence and risk factors for hypercalciuria

Aliberti Ludovica , gamberini maria rita , ziggiotto andrea , verrienti martina , Gagliardi Irene , Zatelli Maria Chiara , Ambrosio Maria Rosaria

Introduction: Thalassaemia syndromes are a group of inherited haemolytic disorders determining chronic anaemia, iron overload and organ damage (through the production of ROS), necessitating of iron chelation therapy. Nowadays, there is scant knowledge on hypercalciuria in thalassaemic Western patients. Therefore, aim of our study was evaluating the prevalence of hypercalciuria and identifying risk factors and clinical consequences associated with its development.<p class="...